美国食品及药物管理局批准 Casgevy 和 lyfgenia：镰状细胞病基因疗法的双重突破

{"title":"美国食品及药物管理局批准 Casgevy 和 lyfgenia：镰状细胞病基因疗法的双重突破","authors":"Z. Rahmat, M. H. Ali, Muhammad Talha, Md. Al Hasibuzzaman","doi":"10.1097/ms9.0000000000002409","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":503882,"journal":{"name":"Annals of Medicine & Surgery","volume":"38 19","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FDA approval of casgevy and lyfgenia: A dual breakthrough in gene therapies for sickle cell disease\",\"authors\":\"Z. Rahmat, M. H. Ali, Muhammad Talha, Md. Al Hasibuzzaman\",\"doi\":\"10.1097/ms9.0000000000002409\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":503882,\"journal\":{\"name\":\"Annals of Medicine & Surgery\",\"volume\":\"38 19\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Medicine & Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ms9.0000000000002409\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine & Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ms9.0000000000002409","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}